Rochira Vincenzo, Balestrieri Antonio, Madeo Bruno, Granata Antonio R M, Carani Cesare
Department of Medicine and Medical Specialties, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy.
J Androl. 2006 Mar-Apr;27(2):165-75. doi: 10.2164/jandrol.05077. Epub 2005 Nov 8.
To study the effects of sildenafil on human sleep-related erections according to the state of androgenization, we evaluated the effects of sildenafil on sleep-related erections in hypogonadal men before and during testosterone replacement treatment and in control subjects. We enrolled 24 hypogonadal men and 24 healthy men as a control group. All hypogonadal subjects had very low testosterone levels (<200 ng/dL [6.9 nmol/L]) [corrected] All subjects underwent nocturnal penile tumescence and rigidity monitoring (NPTRM) for 3 consecutive nights and were randomly assigned to consume either 50 mg of sildenafil or placebo 1 hour before bedtime on the second or third night of nocturnal penile monitoring. The hypogonadal subjects were tested twice, first without replacement treatment (H-T) and then after at least 6 months of testosterone replacement therapy (H+T). The subjects of the control group (C) were tested once. The following parameters of sleep-related erections were analyzed: total number of valid erections, total duration of both rigidity greater than or equal 70% and increase in penile circumference greater than or equal 30 mm, maximum rigidity, and maximum increase in penile circumference. NPTRM parameters were reduced in hypogonadal men before testosterone treatment (H-T+P) when compared with control subjects taking placebo (C+P). NPTRM parameters after testosterone (H+T+P) and sildenafil (H-T+S) administration were similar to that of control subjects taking placebo (C+P). When the statistical analysis was restricted to the hypogonadal men before testosterone treatment, sildenafil alone significantly increased NPTRM parameters when compared with placebo (H-T+S vs H-T+P). Testosterone restored normal erections when administered to hypogonadal subjects (H+T+P vs H-T+P); in hypogonadal men, however, the combined treatment (sildenafil plus testosterone) resulted in the maximum positive effect on NPTRM parameters. When the increase from baseline was analyzed, the effects of testosterone plus sildenafil were greater than the sum of the effects of each drug used alone. In conclusion, sildenafil administered at bedtime improves sleep-related erections in hypogonadal men, suggesting that the nitric oxide pathway may be pharmacologically enrolled and enhanced despite low serum testosterone. Furthermore, these data strongly support the idea of a synergic effect on sleep-related erections of sildenafil and testosterone.
为了根据雄激素化状态研究西地那非对人类与睡眠相关勃起的影响,我们评估了西地那非在性腺功能减退男性睾酮替代治疗前、治疗期间以及对对照组受试者睡眠相关勃起的影响。我们招募了24名性腺功能减退男性和24名健康男性作为对照组。所有性腺功能减退受试者的睾酮水平都非常低(<200 ng/dL [6.9 nmol/L])[校正后]。所有受试者连续3晚接受夜间阴茎肿胀和硬度监测(NPTRM),并在夜间阴茎监测的第二晚或第三晚睡前1小时随机分配服用50 mg西地那非或安慰剂。性腺功能减退受试者进行了两次测试,第一次是在未进行替代治疗时(H-T),然后是在至少6个月的睾酮替代治疗后(H+T)。对照组(C)受试者进行了一次测试。分析了以下与睡眠相关勃起的参数:有效勃起总数、硬度大于或等于70%且阴茎周长增加大于或等于30 mm的总持续时间、最大硬度以及阴茎周长的最大增加量。与服用安慰剂的对照组受试者(C+P)相比,性腺功能减退男性在睾酮治疗前(H-T+P)的NPTRM参数降低。睾酮(H+T+P)和西地那非(H-T+S)给药后的NPTRM参数与服用安慰剂的对照组受试者(C+P)相似。当统计分析仅限于睾酮治疗前的性腺功能减退男性时,与安慰剂相比,单独使用西地那非可显著增加NPTRM参数(H-T+S vs H-T+P)。给性腺功能减退受试者服用睾酮可恢复正常勃起(H+T+P vs H-T+P);然而,在性腺功能减退男性中,联合治疗(西地那非加睾酮)对NPTRM参数产生了最大的积极影响。当分析相对于基线的增加量时,睾酮加西地那非的效果大于单独使用每种药物的效果之和。总之,睡前服用西地那非可改善性腺功能减退男性与睡眠相关的勃起,这表明尽管血清睾酮水平较低,但一氧化氮途径可能在药理学上被激活并增强。此外,这些数据有力地支持了西地那非和睾酮对与睡眠相关勃起具有协同作用的观点。